Reem Ghalib, MD
Gastroenterology · Arlington, TXNPI 1558337782
Payments from drug & device makers
Across 987 payments — averaging $2722.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$580K
- Intercept Pharmaceuticals, Inc.$362K
- Novo Nordisk AS$316K
- Genentech, Inc.$262K
- Boehringer Ingelheim International GmbH$260K
- AbbVie$200K
- plus $706K from 21 others
What the payments were for
- Consulting fees$3,52566%
- Travel & lodging$1,10221%
- Food & beverage$70813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 90 | $580,001 |
| Intercept Pharmaceuticals, Inc. | 94 | $361,689 |
| Novo Nordisk AS | 499 | $316,109 |
| Genentech, Inc. | 21 | $262,340 |
| Boehringer Ingelheim International GmbH | 85 | $259,909 |
| AbbVie(2 entities) | 47 | $200,332 |
| Boehringer Ingelheim | 4 | $164,163 |
| Madrigal Pharmaceuticals | 27 | $152,784 |
| Merck | 14 | $71,174 |
| Novartis | 5 | $65,872 |
| Intercept Pharma Europe Ltd. | 10 | $52,340 |
| Ipsen Bioscience Inc. | 21 | $45,690 |
| Ipsen Pharma SAS | 18 | $41,084 |
| Bristol Myers Squibb | 3 | $32,701 |
| AstraZeneca | 2 | $28,443 |
| E.r. Squibb & Sons, L.L.C. | 3 | $21,204 |
| Boehringer Ingelheim RCV GmbH & Co KG | 27 | $9,977 |
| Astrazeneca UK Limited | 1 | $8,266 |
| Pfizer | 2 | $6,320 |
| Alnylam Pharmaceuticals Inc. | 6 | $6,182 |
| Lilly USA, LLC | 2 | $61 |
| Pinnacle Biologics, Inc | 1 | $28 |
| GSK | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Ardelyx, Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$3,525
How this compares
$2,686,791 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Propranolol Hcl | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Arlington
- Mohammad Al AssiArlington$1.1M
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.